AMD expands quantum partnership with PsiQuantum
AMD announced the expansion of its partnership with PsiQuantum through an undisclosed equity investment and joint work to develop a hybrid computing architecture combining quantum systems with supercomputing and artificial intelligence. The partnership targets scientific applications in chemistry and drug discovery that require independent scientific verification.
DeepLife and 3Billion partner for genetic drug discovery
Parisian artificial intelligence company DeepLife and South Korean genomics firm 3Billion have announced a partnership to develop small-molecule treatments against new drug targets with a focus on genetic modifiers. The agreement integrates the TwinCell virtual cell platform with genomic data from more than 110,000 individuals.
Say goodbye to animal testing? How AI is accelerating drug discovery and saving billions
As the U.S. Food and Drug Administration (FDA) moves toward significantly reducing animal testing, pharmaceutical companies are increasingly adopting artificial intelligence technologies. This revolution promises to cut the time and cost required to bring a new drug to market in half, ultimately leading to cheaper and safer medications.
A revolution in medicine: DeepMind chief pledges to discover new drugs in months instead of years thanks to artificial intelligence
Demis Hassabis, the mastermind behind AlphaFold and Nobel laureate, announces that artificial intelligence will radically shorten the drug development journey. Are we on the threshold of a new era in medicine, or is the road still long?
Anthropic acquires muscular dystrophy treatment startup Mithril
Anthropic has acquired Mithril Medicine, a one-person startup developing treatments for two rare types of muscular dystrophy. The company also published early results from research partnerships with six drug development companies, including Bristol Myers Squibb and Invita.
Burjeel and Avatrial Collaborate for AI-Driven Cancer Drug Discovery
Abu Dhabi-based Burjeel Holdings has signed a memorandum of understanding with British biotechnology company Avatrial during the Abu Dhabi Future Health Summit to explore the development of an AI-powered cancer drug discovery ecosystem. The proposed collaboration combines clinical data, multi-layered molecular analysis, and patient-derived laboratory models.
TikTok CEO predicts major AI scientific breakthroughs
TikTok CEO Shou Zi Chew has affirmed that artificial intelligence technologies will lead to decisive scientific breakthroughs in physics, biotechnology, and materials science over the next few years, noting his parent company ByteDance’s pursuit of expansion in academic and medical research while managing the risks of autonomous agents.
First artificial intelligence model of the human cell unveiled
Startup GenBio AI has unveiled “IdoCell,” representing the world’s first virtual human cell model capable of simulating cellular behavior from DNA and proteins to the complete cell and its drug responses. Nobel laureate biologist David Baker co-founded the project.
OpenAI researcher founds drug discovery startup
Miles Wang, a prominent researcher at OpenAI, is preparing to launch a startup focused on leveraging artificial intelligence for critical drug discovery amid discussions to raise substantial funding valuing the company at $2 billion.
AI-designed drugs from Isomorphic Labs are about to enter human trials
Isomorphic Labs, a Google DeepMind spin-off, is preparing to begin human trials for a drug designed entirely by artificial intelligence in a historic medical milestone.